Why the study?
Does an algorithm including intravenous lidocaine improve management of QT prolongation in COVID-19 patients treated with chloroquine/hydroxychloroquine and azithromycin?
Does an algorithm including intravenous lidocaine improve management of QT prolongation in COVID-19 patients treated with chloroquine/hydroxychloroquine and azithromycin?
Proposes an algorithm for managing QT prolongation in COVID-19 patients receiving chloroquine/hydroxychloroquine and azithromycin, highlighting potential benefits of intravenous lidocaine.
Alerts clinicians to QT-prolonging risk with HCQ/chloroquine in COVID-19; leaves open arrhythmic incidence in larger cohorts.
The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic owing to a newly identified coronavirus, SARS-CoV-2, originating in Wuhan, China, has resulted in significant morbidity and mortality around the world. Early reports have shown improved clinical outcome and viral clearance with the use of chloroquine and hydroxychloroquine.1,2
No takes yet. Share an insight, caveat, or question.
Mitra et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: